Novo Nordisk's Jekyll-and-Hyde Week: A Paediatric Milestone for Semaglutide, a Second Cardiology Casualty
Published on 09/08/2026 at 15:41 | Editorial boerse-global.de
The Danish pharmaceutical giant delivered a study result and a study stoppage on the same day, underscoring just how bifurcated its investment narrative has become. On Monday, Novo Nordisk confirmed that semaglutide, in combination with lifestyle intervention, hit its primary endpoint in obese children aged six to under twelve — a first for such a young demographic. Hours later, the company pulled the plug on two Phase 3 trials for its heart failure candidate ziltivekimab after an independent data monitoring committee concluded a favourable outcome was unlikely.
That juxtaposition captures the tension at the heart of the Novo story: a company whose scientific platform keeps broadening its reach, yet whose pipeline diversification efforts beyond obesity and diabetes keep hitting walls.
Speaking of managing risk — whether in clinical trials or on the factory floor, documenting hazards properly is what separates proactive organisations from reactive ones. A free toolkit with 41 ready-to-use templates and checklists helps you stay ahead of workplace risks before they become costly incidents. Download the free Risk Assessment Toolkit
The Paediatric Data That Broke New Ground
The STEP-Young trial delivered striking figures. Among children receiving treatment, 40.4 percent fell below the obesity threshold after 68 weeks, compared with zero percent in the placebo arm. Notably, more than 85 percent of participants entered the study with severe obesity — class II or III — making the result all the more consequential. No comparable dataset exists for this age group; Eli Lilly has yet to publish anything similar.
The commercial implications, however, are not immediate. Regulatory pathways for paediatric indications are notoriously slow, and the revenue contribution is unlikely to materialise in the near term. What the data does signal is structural: GLP-1 prescribing among US children under twelve has surged more than 300-fold since 2019, according to recent reporting, with Wegovy the most frequently prescribed product. The question for investors is whether the market is evolving from an adult-focused therapy into a lifelong treatment arc spanning childhood through old age.
A Second Setback for Ziltivekimab
The cardiology news was harder to digest. HERMES and ATHENA, both Phase 3 trials evaluating ziltivekimab as an IL-6 inhibitor for heart failure, have been discontinued. This marks the second failure within weeks — the ZEUS study had already collapsed in July. Only the ARTEMIS trial, examining the drug in post-heart-attack patients, remains active, with results expected in the first half of 2027.
The programme's pedigree makes the stumble more conspicuous. Ziltivekimab originated from the 2020 acquisition of Corvidia, a deal that cost Novo Nordisk $725 million. Two failed studies in rapid succession raise uncomfortable questions about capital allocation, even for a company with the financial firepower of Novo.
Context helps, though. Novartis simultaneously announced that its cardiovascular candidate pelacarsen had missed its primary endpoint in an advanced-stage trial. The broader picture suggests that developing new heart drugs is proving difficult across the industry, not just in Bagsværd.
What the Chart Says
The share price reaction has been muted rather than dramatic. The stock traded at €39.83 on Monday, roughly 27 percent below its 52-week high of €54.86 set in January. The relative strength index sits at 46.8, indicating neither overbought nor oversold conditions — the market appears to have absorbed the mixed news without panic.
That measured response makes sense. Ziltivekimab was never central to the investment thesis; semaglutide remains the core, and there the paediatric data provides genuine substance. Yet the stock has struggled to find momentum. Following the German launch of the Wegovy tablet last Friday, shares gave back around 1.6 percent. The current price of €39.42 leaves the stock about 28 percent below its January peak and roughly 2 percent under its 200-day moving average — a picture of sideways drift rather than decisive direction.
The August Signal That Bears Watching
Citi, which reaffirmed a Sell rating on September 2 with a target of DKK 265, points to softening GLP-1 prescription trends from a weekly IQVIA tracker through August 21. Brazilian import data for polypeptide-based hormone medications — a proxy for weight-loss drug demand — fell 22 percent in August compared with July, according to the bank. That is a single regional data point, but it hints at demand elasticity and the creeping reality of generic and biosimilar competition.
Deutsche Bank had already downgraded the stock to Sell in late August, and the ziltivekimab setback is unlikely to soften that stance.
Just as investors watch for early warning signs in clinical data, UK employers need to spot compliance gaps before regulators do. Over 37,000 British companies already use a free toolkit covering risk assessments, checklists and toolbox talks to stay on the right side of health and safety law. Get the free Health & Safety Toolkit
Eyes on London
All roads now lead to September 21, when Novo Nordisk hosts its capital markets day in London with a same-day webcast. Management faces the challenge of weaving together several narrative threads — the paediatric opportunity, the halted heart studies, and softening US prescription trends — into a coherent growth story.
The stock's recent behaviour suggests investors are withholding judgment until then. The scientific engine remains formidable, but the commercial picture is showing early cracks. Whether the current discount to the stock's highs is justified or excessive may well depend on what management says in London — and whether the demand softness visible in one Latin American market proves to be an outlier or a harbinger.
